Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3417-3427

  Rudland, Philip S ^a,d   Platt Higgins, Angela ^a   El Tanani, Mohamed ^a   De Silva Rudland, Suzete ^a   Barraclough, Roger ^a   Winstanley, John H R ^b   Howitt, Rachel ^c   West, Christopher R ^c  

^a School of Biological Sciences Derby Building   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Department of Pathology ^*  (United Kingdom)

^d Cancer Tissue Bank Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; OSTEOPONTIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; SIALOGLYCOPROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037096898     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Worldwide evidence
2. The pattern of metastasis in human breast cancer-methological aspects and influence of prognostic factors
3. Histological grading and prognosis in breast cancer
4. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases
5. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
6. The long term prognostic significance of c-erbB-2 in primary breast cancer
7. Expression of c-erbB-3 gene product in breast cancer
8. C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma-an immunocytochemical study
9. Comparison of two estrogen receptor assays in the prediction of clinical course of patients with advanced breast cancer
10. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer
11. Oestrogen receptors-their long term significance in breast cancer
12. Expression of pS2 estrogen-inducible protein in primary breast cancer
13. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer
14. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas
15. Immunohistochemical detection of p53 protein in mammary carcinoma. An important new independent indicator of prognosis
16. Immunohistochemical p53 tumor suppressor gene protein: Overexpression with prognosis in highly proliferative human mammary adenocarcinoma
17. Prognostic significance of cathepsin-D in patients with breast cancer
18. Impact of molecular biology on the clinical management of breast cancer
19. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells
20. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells
21. Expression of osteopontin in human glioma
22. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts
23. Reduced malignancy of ras-transformed NIH3T3 cells expressing antisense osteopontin RNA
24. Phenotypic instability of rat mammary tumor epithelial cells
25. The identification of osteopontin as a metastatic-related gene product in a rodent mammary tumor model
26. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line
27. Osteopontin: Role in cell signaling and adhesion
28. Osteopontin expression and distribution in human carcinomas
29. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation
30. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival
31. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci
32. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer
33. Osteopontin expression in a group of lymph node negative breast cancer patients
34. Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phases of bone and growth plate in serum
35. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins
36. cDNA cloning, mRNA distribution and heterogeneity, chromosomal localization, and RFLP analysis of human osteopontin (OPN)
37. Comparison of the metastasisinducing protein S100A4 (p9Ka) with other prognostic markers in human breast cancer
38. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer
39. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion and complement-mediated attack
40. Localization of transglutaminase-reactive glutamine residues in bovine osteopontin
41. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
42. Comparative expression of the fibroblast growth factor mRNAs in benign and malignant breast disease
43. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
44. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4
45. Regression models and life tables
46. Improved immunohistochemical staining of osteopontin (OPN) in paraffin-embedded archival bone specimens following antigen retrieval: Anti-human OPN antibody recognizes multiple molecular forms
47. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)
48. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers
49. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer
50. Expression of osteopontin and osteonectin in breast cancer
51. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections
52. Osteopontin
53. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral invasive mammary carcinomas
54. Osteopontin expression in mammary gland development and tumorigenesis
55. Osteopontin expression and function: Role in bone remodeling
56. 3 receptor in breast carcinoma
57. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas
58. 3 potentiate bone resorption
59. The adhesive and migratory effects of osteopontin are mediated by distinct cell surface integrins
60. Overcoming obstacles to metastasis-defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells
61. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo
62. Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
63. Co-expression of osteopontin and CD44v9 in gastric cancer
64. Intracellular OPN is an integral component of the CD44-ERM complex involved in cell migration
65. The clonal evolution of tumor cell populations
66. Cancer metastasis and angiogenesis-an imbalance of positive and negative regulation